A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

The Path Maze is a physical representation of this vision for students, offering a space for students and community members alike to enjoy together.

Self-discipline is the secret ingredient that can transform your life from a series of chaotic moments into a well- planned ...

A U.S. District Judge has set a deadline for the family of Stephen Perkins to replead its case against the City of Decatur.

An international team of scientists have discovered that soap could be important to helping our understanding of complex ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Capital Breakfast's Jordan North, Chris Stark & Sian Welby paid a visit to the haunted London Tombs to try out their ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

A hunt for mountain lions along the Gila River in New Mexico led the hunter, Charles Elliott, and his guide on a chase ...

An anonymous coder, writing to 404media under the fake name Aaron B, has also been feeling the malaise, and he's doing ...

Maze Therapeutics ( NASDAQ: MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...